3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
5
Ovarian Neoplasms
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Healthy Participants
2
Endometrial Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumour
1
Neoplasm Metastasis
1
Moderate Hepatic Impairment
1
Melanoma
1
Hereditary Sensory and Autonomic Neuropathies
1
Hematologic Neoplasms
1
Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)
1
Fallopian Tube Neoplasms
1
Chondrosarcoma
1
Advanced Solid Tumours
1
Advanced Solid Malignancy,
1
Advanced Solid Malignancy
1
Advanced Cancer
1
Interventions
Nivolumab
8
Paclitaxel
6
Sirolimus
5
Bevacizumab
5
temsirolimus
4
Pemetrexed
4
Ipilimumab
4
Docetaxel
4
Carboplatin
4
ARRY-334543
4
Gemcitabine
3
Erlotinib Hydrochloride
3
olaparib
2
linrodostat
2
apatinib
2
anlotinib
2
abemaciclib
2
Vorinostat
2
Sunitinib
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
Everolimus
2
Doxorubicin
2
Dasatinib
2
Chlorogenic Acid
2
Cetuximab
2
6-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline
2
vorolanib
1
vistusertib
1
trametinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Advanced Cancer
×
capivasertib
×
Clear all
NCT02338622
2024-09-26
ComPAKT
Royal Marsden NHS Foundation Trust
Phase 1
Completed
60 enrolled